252 related articles for article (PubMed ID: 31236688)
1. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D; Arab JP; Arrese M
Handb Exp Pharmacol; 2019; 256():237-264. PubMed ID: 31236688
[TBL] [Abstract][Full Text] [Related]
2. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
3. Bile Acids in Cholestasis and its Treatment.
Arab JP; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s53-s57. PubMed ID: 29080340
[TBL] [Abstract][Full Text] [Related]
4. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid.
Piazza F; Montagnani M; Russo C; Azzaroli F; Aldini R; Roda E; Roda A
Dig Liver Dis; 2000 May; 32(4):318-28. PubMed ID: 11515630
[TBL] [Abstract][Full Text] [Related]
5. Bile Acids in Cholestasis and its Treatment.
Pablo Arab J; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16 Suppl 1():S53-S57. PubMed ID: 31196636
[TBL] [Abstract][Full Text] [Related]
6. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture.
Hillaire S; Ballet F; Franco D; Setchell KD; Poupon R
Hepatology; 1995 Jul; 22(1):82-7. PubMed ID: 7601437
[TBL] [Abstract][Full Text] [Related]
7. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
Cifuentes-Silva E; Cabello-Verrugio C
Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
[TBL] [Abstract][Full Text] [Related]
8. Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine-treated rat liver.
Nakai T; Katagiri K; Hoshino M; Hayakawa T; Ohiwa T
Biochem J; 1992 Dec; 288 ( Pt 2)(Pt 2):613-7. PubMed ID: 1361125
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes.
Mališová L; Kováčová Z; Koc M; Kračmerová J; Stich V; Rossmeislová L
PLoS One; 2013; 8(12):e82086. PubMed ID: 24312631
[TBL] [Abstract][Full Text] [Related]
10. The bile acid TUDCA and neurodegenerative disorders: An overview.
Zangerolamo L; Vettorazzi JF; Rosa LRO; Carneiro EM; Barbosa HCL
Life Sci; 2021 May; 272():119252. PubMed ID: 33636170
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1.
Pusl T; Vennegeerts T; Wimmer R; Denk GU; Beuers U; Rust C
Biochem Biophys Res Commun; 2008 Feb; 367(1):208-12. PubMed ID: 18164257
[TBL] [Abstract][Full Text] [Related]
13. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis.
Beuers U; Nathanson MH; Isales CM; Boyer JL
J Clin Invest; 1993 Dec; 92(6):2984-93. PubMed ID: 8254052
[TBL] [Abstract][Full Text] [Related]
14. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
15. Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives.
Kusaczuk M
Cells; 2019 Nov; 8(12):. PubMed ID: 31757001
[TBL] [Abstract][Full Text] [Related]
16. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.
Marzioni M; Francis H; Benedetti A; Ueno Y; Fava G; Venter J; Reichenbach R; Mancino MG; Summers R; Alpini G; Glaser S
Am J Pathol; 2006 Feb; 168(2):398-409. PubMed ID: 16436655
[TBL] [Abstract][Full Text] [Related]
17. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
[TBL] [Abstract][Full Text] [Related]
19. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
20. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
